Latest Clinical Trials
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma National Cancer Institute (NCI) NA
RECRUITING
(Sep 9, 2026)
PHASE2 An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia AstraZeneca NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma ECOG-ACRIN Cancer Research Group NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma Washington University School of Medicine NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) Stichting Hemato-Oncologie voor Volwassenen Nederland NA
RECRUITING
(Sep 1, 2026)
PHASE2 Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) Loxo Oncology, Inc. NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. National Health Research Institutes, Taiwan NA
COMPLETED
(Sep 1, 2026)
PHASE1 Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL AstraZeneca NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) Merck Sharp & Dohme LLC NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies AstraZeneca NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia BeOne Medicines NA
RECRUITING
(Sep 1, 2026)
PHASE3 An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome University of Birmingham NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients AstraZeneca NA
COMPLETED
(Aug 1, 2026)
PHASE3 Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma AstraZeneca NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL German CLL Study Group NA
RECRUITING
(Aug 1, 2026)
PHASE3 A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma AstraZeneca NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma City of Hope Medical Center NA
RECRUITING
(Aug 1, 2026)
PHASE1 Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab AstraZeneca NA
RECRUITING
(Aug 1, 2026)
PHASE2 A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain AstraZeneca NA
RECRUITING
(Aug 1, 2026)
PHASE2 Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL Acerta Pharma BV NA
COMPLETED
(Jul 1, 2026)
PHASE2 A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma M.D. Anderson Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE2 A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. Ascentage Pharma Group Inc. NA
RECRUITING
(Jul 1, 2026)
PHASE3 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma University Health Network, Toronto NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma Academic and Community Cancer Research United NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Acalabrutinib in CNSL Dana-Farber Cancer Institute NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Jennifer Woyach NA
RECRUITING
(Jun 1, 2026)
PHASE2 ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE3 Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma University of Washington NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas UNC Lineberger Comprehensive Cancer Center NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial Fred Hutchinson Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE2 Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study M.D. Anderson Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE2 Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma City of Hope Medical Center NA
NOT YET RECRUITING
(May 1, 2026)
PHASE2 Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies The First Affiliated Hospital of Soochow University NA
NOT YET RECRUITING
(May 1, 2026)
PHASE3 ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Acerta Pharma BV NA
COMPLETED
(Apr 1, 2026)
PHASE1, PHASE2 Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL Weill Medical College of Cornell University NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies AstraZeneca NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) University Hospital Southampton NHS Foundation Trust NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL Massachusetts General Hospital NA
RECRUITING
(Apr 1, 2026)
PHASE2 Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia City of Hope Medical Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) AbbVie NA
RECRUITING
(Apr 1, 2026)
PHASE3 A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy Acerta Pharma BV NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma Washington University School of Medicine NA
COMPLETED
(Mar 1, 2026)
PHASE2 Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma University College, London NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma Jonsson Comprehensive Cancer Center NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Mayo Clinic NA
RECRUITING
(Mar 1, 2026)
PHASE2 
